Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,608,882,256.80, a decrease of 15.00% compared to CNY 1,892,703,843.32 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2019 was CNY 102,211,462.33, down 38.42% from CNY 165,985,941.95 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 100,705,479.18, a decrease of 35.95% compared to CNY 157,234,675.75 in the same period last year[21]. - Basic earnings per share for the first half of 2019 were CNY 0.129, down 38.57% from CNY 0.210 in the same period last year[22]. - The weighted average return on net assets decreased by 0.999 percentage points to 2.876% from 3.875% in the previous year[22]. - The company achieved operating revenue of CNY 1,608.88 million, a decrease of CNY 28.38 million or 15.00% year-on-year[35]. - The pharmaceutical manufacturing segment generated sales revenue of CNY 1,308.84 million, down CNY 16.12 million or 10.96% year-on-year, while the medical services segment revenue was CNY 295.83 million, a decrease of CNY 12.62 million or 29.90% year-on-year[35]. - The company reported a net loss of CNY 408,184.04 in investment income, compared to a loss of CNY 16,317.95 in the previous year[114]. - The total comprehensive income for the first half of 2019 was CNY 92.03 million, compared to CNY 173.38 million in the previous year, showing a decrease of approximately 46.8%[116]. Cash Flow and Assets - The net cash flow from operating activities was CNY 191,579,301.27, a significant improvement from a negative cash flow of CNY -97,200,424.40 in the previous year[21]. - The company's cash flow from operating activities was CNY 191.58 million, a significant recovery from a negative CNY 97.20 million in the previous period[37]. - The company's cash and cash equivalents at the end of the period were CNY 755.21 million, representing 13.53% of total assets, an increase of 37.11% compared to the previous period[39]. - The company's total assets at the end of the reporting period were CNY 5,581,768,582.24, a decrease of 13.80% from CNY 6,475,568,370.27 at the end of the previous year[21]. - The company's total assets decreased to CNY 4,637,391,462.08 from CNY 5,271,149,907.30, reflecting a decline of 12.0%[112]. - The company's cash and cash equivalents increased to CNY 450,374,412.28, compared to CNY 346,382,729.23 at the end of 2018, representing a growth of 29.9%[110]. - The company's total liabilities decreased to CNY 1,822.22 million from CNY 2,517.63 million[108]. - The total owner's equity at the end of the reporting period is CNY 4,830,208,819.43, showing a significant increase from the previous period[136]. Research and Development - Research and development expenses increased by 158.45% to CNY 72.98 million, reflecting a rise in upfront costs for ongoing projects[37]. - The company is focused on continuous product innovation and has a robust pipeline for new drug development[28]. - The company's research and development expenses increased to CNY 57.66 million in the first half of 2019, up from CNY 10.52 million in the same period of 2018, marking a growth of about 447.5%[117]. Market and Product Development - The company has not disclosed any plans for new product development or market expansion in this report[21]. - The company has a product portfolio of 149 varieties and 194 drug production approvals, with 79 varieties included in the national medical insurance catalog[30]. - The company is transitioning to a comprehensive pharmaceutical enterprise, integrating modern traditional Chinese medicine, chemical drugs, and biological drugs[28]. - The company has established a national苗药工程技术研究中心, marking a significant advancement in the research of ethnic medicine[30]. - The company is leveraging healthcare reforms to expand its sales network and improve market penetration[28]. Financial Risks and Compliance - The company faces R&D risks due to high investment and competition in the pharmaceutical industry, which may affect product sales and development outcomes[46]. - The company is adapting to new drug pricing policies and market risks, necessitating a shift towards innovation and market expansion[46]. - Quality control risks are heightened by new regulations and standards in drug development and production, requiring stringent compliance measures[46]. - Regulatory risks include potential exclusion from national medical insurance directories, which could adversely affect production and operations[47]. - Environmental policy risks may increase operational costs and impact production processes due to stricter compliance requirements[47]. Environmental Compliance - Environmental emissions data indicates that the company meets the pollution discharge standards for wastewater and air emissions[65]. - The total amount of CODcr emissions is 2.64 tons per year, with no exceedance of the pollution discharge standards[65]. - The company has a solid waste disposal plan, with 1845 tons of waste handled by authorized companies[66]. - The company has constructed a wastewater treatment plant with a capacity of 2000m³/d, and Chang'an Pharmaceutical has a 50m³/d wastewater treatment plant, both operating stably[67]. - The company utilizes clean energy natural gas for fuel, significantly reducing pollutant emissions, and the canteen's oil fume treatment system effectively meets discharge standards[67]. Corporate Governance - The company has appointed a new general manager, Dou Qiling, while Lang Hongping transitioned to co-president and vice chairman[87]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[84]. - The company has not made any changes to its accounting firm during the audit period[55]. - There are no major related party transactions reported during the period[57]. Accounting and Financial Reporting - The financial report for the first half of 2019 was approved by the board of directors on August 27, 2019[149]. - The company's accounting currency is Renminbi (RMB)[162]. - The company has not established any subsidiaries that are not included in the consolidation scope for the current period[157]. - The company has a 12-month operating cycle[161]. - The company recognizes the difference between the consideration received from the disposal of equity investments and the fair value of remaining equity investments as investment income on the date control is lost[171].

证券代码：600594 证券简称：益佰制药 公告编号：2019-034 债券代码：143338 债券简称：17 益佰 01 贵州益佰制药股份有限公司 关于参加 2019 年贵州上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、可持 续发展等投资者所关心的问题，贵州益佰制药股份有限公司（以下简称"公司"） 定于2019年6月5日下午14:00-17:00参加由贵州证监局主办，贵州证券业协会、 深圳市全景网络有限公司协办的主题为"股东来了——构建和谐投资者关系" 2019年贵州上市公司投资者网上集体接待日活动。现将有关事项公告如下： 本次集体接待日网上交流网址：投资者可以登录http://rs.p5w.net进入专 区页面参与交流。 出席本次集体接待日的人员有：公司董事长兼总经理窦啟玲女士、财务总监 代远富先生、董事会秘书许淼先生。 欢迎广大投资者积极参与。 特此公告。 贵州益佰制药股份有限公司董事会 2019 年 6 月 ...

贵州益佰制药股份有限公司 2019 年第一季度报告 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 2019 年第一季度报告 （修订版） 1 / 25 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 9 | 贵州益佰制药股份有限公司 2019 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 汪志伟 | 董事 | 因工作原因 | 窦啟玲 | | 彭文宗 | 独立董事 | 因工作原因 | 王新华 | 1.3 公司负责人窦啟玲、主管会计工作负责人窦啟玲及会计机构负责人（会计主管人员）代远富保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2 ...

贵州益佰制药股份有限公司 2019 年第一季度报告 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 2019 年第一季度报告 1 / 25 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 9 | 贵州益佰制药股份有限公司 2019 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 汪志伟 | 董事 | 因工作原因 | 窦啟玲 | | 彭文宗 | 独立董事 | 因工作原因 | 王新华 | 1.3 公司负责人窦啟玲、主管会计工作负责人窦啟玲及会计机构负责人（会计主管人员）代远富保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财 ...

Financial Performance - The company reported a net profit attributable to shareholders of -725,495,413.59 RMB for the year 2018, with the parent company experiencing a net loss of -814,805,289.10 RMB[6]. - The company has not achieved profitability in 2018, thus no legal surplus reserves will be allocated[6]. - The company's operating revenue for 2018 was approximately ¥3.88 billion, an increase of 1.98% compared to ¥3.81 billion in 2017[21]. - The net profit attributable to shareholders was a loss of approximately ¥725 million, representing a decrease of 287.21% from a profit of ¥387 million in 2017[21]. - The basic earnings per share for 2018 was -¥0.916, a decline of 287.32% compared to ¥0.489 in 2017[22]. - The weighted average return on equity decreased to -18.71% in 2018, down 28.193 percentage points from 9.483% in 2017[22]. - The total assets at the end of 2018 were approximately ¥6.48 billion, a decrease of 9.99% from ¥7.19 billion at the end of 2017[21]. - The cash flow from operating activities for 2018 was approximately ¥214 million, a decrease of 68.57% compared to ¥682 million in 2017[21]. - The company reported non-recurring gains of approximately ¥47.39 million in 2018, compared to ¥50.29 million in 2017[26]. Dividend and Profit Distribution - The company will not distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the year 2018 due to its current operational situation and strategic planning[6]. - The company has not proposed any cash profit distribution plan for 2018 due to the lack of profit, as the parent company reported a net loss of CNY -814,805,289.10[113]. - The company’s net profit available for distribution to shareholders as of December 31, 2018, was CNY 1,045,004,910.66[112]. - The company executed a cash dividend plan for the year 2017, distributing CNY 0.50 per 10 shares, totaling CNY 39,596,370.00[111]. Audit and Compliance - The company has received a standard unqualified audit report from Beijing Zhongzheng Tiantong Accounting Firm[6]. - The company’s financial report has been confirmed for accuracy and completeness by its management team[6]. - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has made adjustments to its accounting policies in response to new regulations issued by the Ministry of Finance, which do not affect profit or asset levels[118]. - The company has engaged Beijing Zhongzheng Tiantong Accounting Firm for auditing services, with a fee of CNY 680,000 for the year[121]. Market and Industry Overview - The pharmaceutical industry in 2018 saw a total revenue of ¥2.43 trillion, with a year-on-year growth of 12.4%[33]. - The expected sales revenue for the pharmaceutical terminal market in 2018 was approximately ¥1.71 trillion, with a growth rate of 6.3%[33]. - The pharmaceutical industry in China is experiencing a "golden decade" of high growth, driven by increasing medical expenditures and healthcare policy expansions, although growth has slowed recently due to policy changes[98]. - In 2018, the pharmaceutical industry faced challenges such as declining drug prices and rising raw material costs, leading to a low growth rate compared to the previous year[99]. Research and Development - The company focuses on drug research and development across various therapeutic areas, including oncology and cardiovascular diseases[30]. - The company plans to enhance R&D efficiency and focus on the quality and timeliness of new product development[45]. - The company’s R&D expenses amounted to 7,677.55 million RMB, reflecting a year-on-year increase of 7.52%[48]. - The company is focusing on developing new chemical generic injectable drugs to expedite production approvals[84]. - The company has established a research and development center and aims to obtain at least 10 production approvals for generic drugs over the next five years[75][77]. Environmental Compliance - The company adheres to environmental protection regulations and has implemented measures to reduce emissions, including a total COD discharge of 2.64 tons per year[130]. - The company has established a wastewater treatment plant with a capacity of 2000m³/d, while Chang'an Pharmaceutical has a 50m³/d plant and Chaoyang Hospital has a 1000m³/d plant, all operating stably[133]. - The company has achieved compliance with environmental protection licenses and regulations for all its facilities[136]. - The company has committed to continuous improvement in environmental practices, including clean production initiatives and source reduction measures[141]. Shareholder Structure and Governance - The total number of common stock shareholders at the end of the reporting period was 61,807, an increase from 61,746 at the end of the previous month[146]. - Dou Qiling is identified as the actual controller of the company, with no foreign residency rights[152]. - The company does not have any controlling shareholder, as Dou Qiling is the only significant shareholder[152]. - The company has maintained a stable shareholding structure with no significant changes among independent directors[159]. - The company emphasizes information disclosure and investor relations management, ensuring timely and accurate disclosure of significant information[184]. Employee Welfare and Training - The company has a commitment to employee welfare, providing free health checks and organizing vocational training to enhance employee skills[126]. - The training plan focuses on talent development and professional skills enhancement, aiming to build a robust talent system to meet future challenges[177]. - The total number of employees in the parent company is 3,812, while the total number of employees in major subsidiaries is 5,165, resulting in a combined total of 8,977 employees[175]. Strategic Initiatives - The company is actively pursuing a strategy of mergers and acquisitions to support its growth and market expansion[102]. - The company plans to strengthen its marketing efforts by increasing market coverage and enhancing brand promotion, utilizing big data for better market analysis[103]. - The management provided an optimistic outlook, guiding for a revenue growth of 18% for the upcoming fiscal year[163].

2018 年第三季度报告 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 2018 年第三季度报告 1 / 20 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 4 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.4 本公司第三季度报告未经审计。 3 / 20 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人窦啟玲、主管会计工作负责人郎洪平及会计机构负责人（会计主管人员）代远富保证 季度报告中财务报表的真实、准确、完整。 2018 年第三季度报告 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | （7－9 月） | ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 1,892,703,843.32, a decrease of 3.03% compared to CNY 1,951,888,204.70 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 165,985,941.95, down 9.63% from CNY 183,667,437.25 in the previous year[19]. - The net cash flow from operating activities was negative CNY 97,200,424.40, a significant decline of 135.02% compared to CNY 277,534,025.53 in the same period last year[19]. - The basic earnings per share for the first half of 2018 was CNY 0.210, a decrease of 9.48% compared to CNY 0.232 in the same period last year[20]. - The weighted average return on net assets was 3.875%, down 0.68 percentage points from 4.555% in the previous year[20]. - The pharmaceutical industrial segment generated sales revenue of CNY 1,470,026,300, a decline of 7.64% year-on-year, while the medical services segment increased by 17.50% to CNY 422,036,000[36]. - Net profit attributable to the parent company was CNY 165,985,900, down 9.63% year-on-year, primarily due to performance drag from treatment centers and newly established hospitals[36]. - The company achieved operating revenue of CNY 1,892,703,843.32, a decrease of 3.03% compared to the previous year[36]. - The company reported a decrease in current assets from CNY 2,652,614,527.77 at the beginning of the period to CNY 2,608,552,241.52 at the end of the period, reflecting a decline of approximately 1.66%[112]. - The company's cash and cash equivalents decreased from CNY 1,165,547,188.51 to CNY 866,276,543.65, a reduction of about 25.7%[112]. - The accounts receivable increased significantly from CNY 382,526,769.74 to CNY 684,549,229.26, representing an increase of approximately 79.0%[112]. - The company's total liabilities decreased slightly from 34.83% to 34.04%, a reduction of 0.79%[107]. - The interest coverage ratio (EBITDA interest coverage) fell from 7.67 to 5.44, a decline of approximately 29.07%[107]. - The interest payment ratio decreased from 100% to 66.58%, a drop of 33.42% due to increased interest obligations from the 2017 bond issuance[107]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,383,444,051.84, an increase of 2.63% from CNY 7,194,494,634.45 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 2.90% to CNY 4,403,953,159.94 from CNY 4,280,028,481.52 at the end of the previous year[19]. - Long-term equity investments rose by 8.28% to CNY 3,223,503,300, indicating growth in strategic investments[45]. - The company's total liabilities amounted to ¥2,553,235,232.41, compared to ¥2,505,610,751.00, indicating an increase of around 1.9%[115]. - Current liabilities totaled ¥1,733,713,469.27, an increase from ¥1,680,191,446.15, reflecting a rise of about 3.2%[115]. - Non-current liabilities decreased slightly to ¥819,521,763.14 from ¥825,419,304.85, a decline of approximately 0.1%[115]. Market and Industry Insights - The company focuses on the production and sales of pharmaceuticals in oncology, cardiovascular, gynecology, pediatrics, orthopedics, and respiratory fields, with a total of 209 approved drug varieties, of which 168 are included in the national medical insurance catalog[24]. - The Chinese pharmaceutical market's terminal sales increased from 809.7 billion yuan in 2011 to 1,497.5 billion yuan in 2016, with a compound annual growth rate of 13.08%[27]. - The government’s health expenditure increased from 155.3 billion yuan in 2005 to 1,247.5 billion yuan in 2015, with a compound annual growth rate of 23.17%[28]. - The healthcare service demand in China is driven by a growing elderly population, with over 130 million people aged 65 and above as of 2014[27]. - The number of private hospitals in China has surpassed public hospitals, reflecting a shift in the healthcare landscape and increasing acceptance of private medical institutions[30]. Risks and Challenges - The company faces market risks due to fluctuations in the macroeconomic environment, which may adversely affect the demand for pharmaceutical products[53]. - Rising raw material prices, particularly for traditional Chinese medicine, pose a risk to the company's operating performance[54]. - The company is exposed to competition risk from emerging substitute drugs that may impact sales of its core products[53]. - Regulatory risks include potential exclusion from the national medical insurance directory, which could negatively affect production and operations[54]. - The company is at risk of significant adverse impacts if the government reduces the fixed retail prices of its products[54]. - New drug development is capital-intensive and time-consuming, with high risks associated with regulatory approval processes[55]. - The loss of core technical personnel could severely affect the company's competitive edge and operational capabilities[55]. - Environmental policy changes may increase operational costs and impact the company's performance due to stricter compliance requirements[56]. Corporate Governance and Compliance - The company did not report any significant risks or non-operational fund occupation by controlling shareholders[6]. - The company reported no significant litigation or arbitration matters during the reporting period[66]. - There were no major related party transactions disclosed in the interim announcements[68]. - The company has not disclosed any significant contracts or their performance during the reporting period[69]. - The company has not proposed any profit distribution or capital reserve transfer for the reporting period[61]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[66]. - The company has not reported any significant changes in its integrity status or that of its major stakeholders[66]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit and has met the emission standards for wastewater and waste gas[72]. - The total wastewater discharge was compliant with the standards, with CODcr at 8.67 tons/year and BOD5 at 2.71 tons/year[72]. - The company reported a total of 2904 tons of domestic waste, which is handled by a local sanitation station[72]. - The company has established a wastewater treatment facility with a capacity of 2000m³/d, and other facilities with capacities of 50t/d and 1000m³/d, all operating stably[74]. - The company utilizes clean energy natural gas for fuel, significantly reducing pollutant emissions from its operations[74]. - No major environmental pollution incidents or complaints were reported during the reporting period[74]. - The company has obtained all necessary environmental protection administrative licenses as required by national or local authorities[76]. - Emergency response plans for environmental incidents have been developed and implemented by the company[77]. - Third-party monitoring has confirmed that all pollutant discharge indicators are within compliance limits[78]. Strategic Investments and Growth - The company has a strategic focus on expanding its oncology medical services, leveraging its product advantages to enhance service offerings[24]. - The company has a specialized production management model adhering to GMP standards, ensuring quality control throughout the production process[25]. - The company employs a unified group sales management model, utilizing both self-operated and agency sales methods to cover various sales channels[25]. - The company has initiated discussions for potential mergers and acquisitions to enhance its product portfolio and market reach[182]. - The company is actively pursuing mergers and acquisitions to enhance its portfolio in the healthcare sector, as evidenced by its investments in multiple medical technology firms[158]. - The company is focusing on technological development and consulting services in the medical field, with significant investments in subsidiaries dedicated to medical technology research and development[158]. Research and Development - The company’s R&D expenditure increased by 20.59% to CNY 34,589,160.70, reflecting a strategic investment in innovation[39]. - Research and development expenses increased by 10%, focusing on innovative drug formulations and delivery systems[182]. - The company holds 118 authorized invention patents, focusing on oncology, cardiovascular, cough relief, gynecology, and health products[35]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,329[83]. - The largest shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total shares[85]. - The company has not experienced any changes in its share capital structure during the reporting period[82]. - The company distributed 39,596,370.00 RMB to shareholders, indicating a focus on returning value to investors despite the losses reported[142]. - The retained earnings decreased by 39,596,370.00 RMB, highlighting the impact of profit distribution on the overall equity[142].

Financial Performance - The net profit attributable to the parent company for 2017 was CNY 387,529,793.21, with a statutory reserve fund of CNY 16,985,988.01 deducted, resulting in a distributable profit of CNY 2,438,258,413.63[6] - The company reported an increase in undistributed profits carried forward to the next year, amounting to CNY 2,115,230,252.43[6] - The company’s operating revenue for 2017 was approximately CNY 3.81 billion, representing a 3.28% increase compared to CNY 3.69 billion in 2016[22] - The net profit attributable to shareholders of the listed company was CNY 387.53 million, a slight increase of 0.69% from CNY 384.86 million in 2016[22] - The basic earnings per share for 2017 was CNY 0.489, up 0.62% from CNY 0.486 in 2016[23] - The weighted average return on equity decreased to 9.48%, down 0.78 percentage points from 10.27% in 2016[23] - The net cash flow from operating activities increased significantly by 79.12% to CNY 681.78 million from CNY 380.62 million in 2016[22] - Total assets at the end of 2017 reached CNY 7.19 billion, a 9.19% increase from CNY 6.59 billion at the end of 2016[22] - The company reported a net profit of CNY 100.80 million in Q1 2017, with a notable increase in Q3 to CNY 132.58 million[27] - Non-recurring gains and losses for 2017 totaled CNY 50.29 million, compared to CNY 17.02 million in 2016[28] Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.50 per 10 shares, totaling CNY 39,596,370.00, based on a total share capital of 791,927,400 shares as of December 31, 2017[6] - The company distributed a cash dividend of 0.60 yuan per 10 shares, totaling 47,515,644 yuan for the 2016 fiscal year[120] Corporate Governance - The company has not faced any major litigation or arbitration matters during the reporting period[127] - There are no significant related party transactions reported during the year[128] - The company has not encountered any risks of suspension or termination of listing[127] - The company has not made any changes to accounting policies or estimates during the reporting period[126] - The company has engaged Beijing Zhongzheng Tiantong Accounting Firm for auditing services, with a fee of RMB 680,000 for the year[126] - The company has established a comprehensive corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring the maximization of shareholder interests and improved profitability[181] - The company has maintained complete operational independence from its controlling shareholder, with no incidents of fund or asset occupation by the major shareholder reported[182] - The board of directors has established four specialized committees: the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, enhancing the governance framework[183] - The company has reported no significant discrepancies with the requirements set by the China Securities Regulatory Commission regarding corporate governance[185] Market and Industry Trends - The pharmaceutical industry is projected to experience a slowdown in growth due to policy impacts, with the terminal market sales scale reaching ¥1,611.8 billion, a 7.6% year-on-year increase[65] - In 2016, China's pharmaceutical industry sales revenue reached CNY 2,946.3 billion, with a year-on-year growth of 10.3%, marking a recovery from five consecutive years of decline[35] - The compound annual growth rate (CAGR) of China's drug market terminal sales from 2011 to 2016 was 13.08%, increasing from CNY 809.7 billion to CNY 1,497.5 billion[35] - The company faces risks from macroeconomic fluctuations that could negatively impact demand for pharmaceutical products[112] - Rising raw material prices, particularly for traditional Chinese medicine, pose a risk to the company's operating performance[112] Research and Development - The company has invested in 25 tumor treatment center projects and established seven tumor doctor groups to enhance its medical service capabilities[32] - The company’s R&D expenditure increased by 16.15% to 21,950.77 million RMB compared to the previous year[48] - The total R&D investment amounted to CNY 219,507,663.63, representing 5.76% of the operating revenue, with 67.47% of the R&D costs capitalized[57] - The company focuses on core therapeutic areas including anti-tumor, cardiovascular, and cough-relief medications, collaborating with universities and research institutions for product innovation[78] - The company’s major product, 甲磺酸达比加群酯胶囊, has a cumulative R&D investment of CNY 955.26 million and is in the I phase of clinical trials[85] Environmental Responsibility - The company has implemented a production model focused on pollution reduction and environmental protection, aligning with the ecological civilization construction in Guiyang[132] - The company has constructed a wastewater treatment plant with a capacity of 2000m³/d, which is operating stably[139] - The company has implemented a clean energy strategy by using natural gas as fuel, significantly reducing pollutant emissions[139] - The company has established solid waste facilities including one hazardous waste storage area and one emergency waste area, complying with environmental regulations[139] - The company has obtained all necessary environmental protection administrative permits as required by national or local authorities[140] Employee Management - The total number of employees in the parent company is 2,273, while the total number of employees in major subsidiaries is 4,738, resulting in a combined total of 7,011 employees[174] - The total remuneration for 17 directors, supervisors, and senior management personnel during the reporting period amounted to 2.6598 million yuan[172] - The company emphasizes a salary policy based on employee contributions, with different compensation structures for various roles, including a salary system for senior management and a commission-based system for sales personnel[175] - The training plan for 2017 focuses on enhancing the company's comprehensive strength and talent system, combining internal and external training methods[176] Future Outlook - The company aims to achieve an operating revenue of 4.3 billion yuan in 2018, focusing on optimizing marketing management and enhancing product quality[111] - The company plans to expand its market presence through new product development and strategic acquisitions in the coming years[166] - Future guidance suggests a continued upward trend in revenue and profit margins, driven by market expansion strategies[166] - The management team emphasized the importance of quality control and regulatory compliance in maintaining competitive advantage[166]

Financial Performance - Operating revenue for the period was CNY 963,846,291.14, representing a 3.53% increase year-on-year[6] - Net profit attributable to shareholders increased by 4.41% to CNY 97,464,207.66 compared to the same period last year[6] - Basic and diluted earnings per share were both CNY 0.128, a slight increase of 0.79% compared to the previous year[6] - Total revenue for Q1 2018 was CNY 963.85 million, an increase of 3.9% compared to CNY 930.95 million in the same period last year[23] - Net profit for Q1 2018 was CNY 106.28 million, a decrease of 8.0% from CNY 115.53 million in Q1 2017[24] - Earnings per share for Q1 2018 were CNY 0.128, slightly up from CNY 0.127 in the previous year[25] - The company’s total comprehensive income for Q1 2018 was CNY 25,260,032.72, reflecting a decrease from CNY 37,977,303.93 in the previous year[27] Asset and Liability Changes - Total assets increased by 3.44% to CNY 7,442,224,288.23 compared to the end of the previous year[6] - Total assets as of March 31, 2018, were 7,442,224,288.23, an increase from 7,194,494,634.45 at the beginning of the year[17] - Current assets totaled 2,704,309,076.47, up from 2,652,614,527.77 at the beginning of the year[16] - Total liabilities increased to 2,643,488,473.22 from 2,505,610,751.00, reflecting a rise in short-term borrowings[18] - Total liabilities increased to CNY 2.40 billion in Q1 2018, up from CNY 2.32 billion in Q1 2017, representing a rise of 3.5%[22] Cash Flow Analysis - Cash flow from operating activities showed a significant decline of 151.73%, resulting in a net cash outflow of CNY -154,209,766.34[6] - Cash flow from operating activities was -154,209,766.34, a decrease of -151.73% compared to 298,100,170.76, primarily due to slower sales collection[14] - Cash flow from investing activities was -109,826,519.96, an increase of 76.08% compared to -62,374,276.65, mainly due to payments for equity in Fulin Hospital[14] - Operating cash flow for Q1 2018 was negative CNY 154,209,766.34, compared to a positive CNY 298,100,170.76 in Q1 2017[29] - Investment activities resulted in a net cash outflow of CNY 109,826,519.96, compared to a net outflow of CNY 62,374,276.65 in the same period last year[30] - Financing activities generated a net cash inflow of CNY 21,300,884.24, an increase from CNY 9,007,659.03 in Q1 2017[30] Receivables and Payables - Accounts receivable increased by 71.52% to CNY 656,119,605.73, attributed to slower sales collection[11] - Prepayments rose by 44.19% to CNY 53,004,971.63 due to increased project payments[11] - Other receivables increased by 64.91% to CNY 136,166,065.59, mainly due to increased advances to counterparties[11] - Interest payable surged by 165.64% to CNY 15,378,303.83, primarily due to increased interest accrual on bonds[11] Investment and Income Changes - Investment income decreased to 0.00 from -394,876.37, a change of -100.00% due to unrecognized investment losses[13] - Other income increased to 4,247,778.95 from 0.00, a change of 100.00% due to adjustments in financial reporting format[13] - Operating income decreased to 1,133,720.29 from 10,060,290.15, a change of -88.73% attributed to reduced non-operating expenses[13] Cost Management - Total operating costs for Q1 2018 were CNY 845.94 million, up 4.5% from CNY 809.50 million in Q1 2017[24] - The company reported a decrease in sales expenses to CNY 453.19 million from CNY 433.16 million, reflecting a strategic focus on cost management[24] - The company incurred total operating expenses of CNY 1,037,873,286.06, an increase from CNY 927,747,737.99 in the previous year[29] Equity and Capital Structure - The company has maintained a stable capital structure with total equity at CNY 3.77 billion, slightly up from CNY 3.74 billion in the previous year[22] - Minority interest decreased to 417,385,316.33 from 408,855,401.93, a change of -2.00% due to changes in the consolidation scope[18] Cash and Liquidity - Cash and cash equivalents decreased to 950,778,514.09 from 1,165,547,188.51, indicating a reduction in liquidity[16] - The cash and cash equivalents at the end of Q1 2018 were CNY 1,257,299,363.09, down from CNY 1,521,715,042.81 at the end of Q1 2017[30] - The company paid CNY 263,149,389.20 to employees in Q1 2018, significantly higher than CNY 112,495,805.40 in the same period last year[29]

2017 年第三季度报告 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 2017 年第三季度报告 1 / 20 | 目录 | | --- | 二、 公司基本情况 2.1 主要财务数据 3 / 20 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年 度末增减(%) 总资产 6,924,066,535.09 6,588,915,234.61 5.09 归属于上市公司股东的净资产 4,208,936,681.52 3,940,357,059.78 6.82 年初至报告期末 （1-9 月） 上年初至上年报告期 末（1-9 月） 比上年同期增减(%) 经营活动产生的现金流量净额 477,190,894.72 265,913,002.71 79.45 年初至报告期末 （1-9 月） 上年初至上年报告期 末（1-9 月） 比上年同期增减（%） 营业收入 2,874,507,001.01 2,684,674,010.28 7.07 归属于上市公司股东的净利润 316,247,812.67 290,171,096.29 8.99 归属于上市公司股东的扣除非 经常性损益的净利润 298,84 ...